Evidence map›Paper›PMID 31177983›Full record

ArticleStroke2019

Antiplatelet Therapy After Noncardioembolic Stroke.

Jacoba P Greving, Hans-Christoph Diener, Johannes B Reitsma, Philip M Bath, László Csiba, Werner Hacke, L Jaap Kappelle, Peter J Koudstaal, Didier Leys, Jean-Louis Mas and 2 more

Open access · greenAbstract readNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Article in Stroke, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Antiplatelet Use in Ischemic Stroke.The Annals of pharmacotherapy · 2022
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Drugs in secondary stroke prevention.Australian prescriber · 2021
    Review
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 10 institutions in 6 countries.

Jacoba P GrevingFrom the Julius Center for Health Sciences and Primary Care (J.P.G., J.B.R., A.A.).
Hans-Christoph DienerDepartment of Neurology, University Hospital Essen, Germany (H.-C.D.).
Johannes B ReitsmaFrom the Julius Center for Health Sciences and Primary Care (J.P.G., J.B.R., A.A.).
Philip M BathStroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham, United Kingdom (P.M.B.).
László CsibaDepartment of Neurology, University of Debrecen Medical and Health Science Center, Hungary (L.C.).
Werner HackeDepartment of Neurology, University of Heidelberg, Germany (W.H.).
L Jaap KappelleDepartment of Neurology and Neurosurgery (L.J.K., A.A.), UMC Utrecht, Utrecht University, the Netherlands.
Peter J KoudstaalDepartment of Neurology, Erasmus MC, Rotterdam, the Netherlands (P.J.K.).
Didier LeysDepartment of Neurology, Roger Salengro Hospital, Lille, France (D.L.).
Jean-Louis MasDepartment of Neurology, Hôpital Sainte-Anne, Université Paris Descartes, France (J.-L.M.).
Ralph L SaccoDepartment of Neurology, Miller School of Medicine, University of Miami, Coral Gables, FL (R.L.S.).
Ale AlgraFrom the Julius Center for Health Sciences and Primary Care (J.P.G., J.B.R., A.A.).
Oklahoma State University Center for Health Sciences · USUtrecht University · NLCentre Hospitalier Sainte-Anne · FRErasmus University Rotterdam · NLEssen University Hospital · DEHeidelberg University · DEHôpital Roger Salengro · FRUniversity of Debrecen · HUUniversity of Miami · USUniversity of Nottingham · GB

Funding

Department of Health 10/104/24
6 · The paper itself

Abstract

Background and Purpose- We assessed the efficacy and safety of antiplatelet agents after noncardioembolic stroke or transient ischemic attack and examined how these vary according to patients' demographic and clinical characteristics. Methods- We did a network meta-analysis (NMA) of data from 6 randomized trials of the effects of commonly prescribed antiplatelet agents in the long-term (≥3 months) secondary prevention of noncardioembolic stroke or transient ischemic attack. Individual patient data from 43 112 patients were pooled and reanalyzed. Main outcomes were serious vascular events (nonfatal stroke, nonfatal myocardial infarction, or vascular death), major bleeding, and net clinical benefit (serious vascular event or major bleeding). Subgroup analyses were done according to age, sex, ethnicity, hypertension, qualifying diagnosis, type of vessel involved (large versus small vessel disease), and time from qualifying event to randomization. Results- Aspirin/dipyridamole combination (RR

Indexed as

AgedAged, 80 and overAspirinCerebrovascular DisordersClopidogrelDipyridamoleDrug Therapy, CombinationFemaleHemorrhageHumansIschemic Attack, TransientMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsRiskAspirinClopidogrelDipyridamolePlatelet Aggregation InhibitorsTiclopidineantiplatelet agentsefficacymyocardial infarctionsecondary preventionstroke

Identifiers

PMID31177983
PMCPMC6594726
OpenAlexW2953466345

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.